Fundraising FoxVida Ventures — 2025 Investments
3 investments dated 2025 · listed companies and verified rows first · show all
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)
Board seatHelen S. Kim· per SEC Form D
Co-investorsAju IB InvestmentEcoR1 CapitalEvolution VC PartnersMPM BioImpactOrbiMedOUP (Osage University Partners)+6 more
Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Timothy A. Springer(Co-Founder)Andrew C. Kruse(Director)Alise Reicin(Executive Officer, Director)inDaniel Lochner(Executive Officer)Marc Schwabish(Executive Officer)inPeter McNamara(Executive Officer)in
Board seatStefan Vitorovic· per SEC Form D
Co-investorsEcoR1 CapitalAlly Bridge GroupClarus VenturesFarallon EquitiesPolaris PartnersSoleus Capital
Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Diego, US
Brent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)
BoardTIM LOHOFF(Director)Edward Hurwitz(Director)
Co-investorsDroia VenturesNovartis Venture FundDigitalis VenturesForbionLightspeed Venture PartnersMPM BioImpact+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.